BBPA Metal Complexes for Targeted Bone Metastasis Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteolytic metastases, such as bisphosphonates, suffer from poor absorption and high doses due to their low bioavailability, leading to undesirable side effects and reduced quality of life for patients, while existing drug delivery systems lack specificity and efficacy in targeting bone metastases.
Innovation Solution
Development of benzene 1,4-bis(bisphosphonic acid) (BBPA) based metal complexes with bioactive metals like Ca2+, Zn2+, and Mg2+, which form porous structures capable of encapsulating drugs and binding to the bone microenvironment, enhancing drug delivery and release profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orally administered bisphosphonates are used to treat osteolytic metastases, then bone density increases through sclerosis stimulation, but absorption is poor (1-2%) requiring high doses that cause undesirable side effects
Solution Approach 1:
The patent introduces metal-organic frameworks (MOFs) as intermediary carriers that encapsulate bisphosphonate drugs. These MOFs serve as mediators between the drug and the body, enabling controlled release and improving bioavailability without requiring high doses, thus reducing side effects while maintaining treatment efficacy.
Solution Approach 2:
The patent utilizes porous metal-organic framework structures with high surface area and tunable pore sizes to load and release bisphosphonate drugs. The porous structure enables high drug loading capacity and controlled release kinetics, improving absorption efficiency and reducing the need for high dosing.
2Reliability
If high doses of bisphosphonates are administered to compensate for poor absorption, then treatment efficacy is maintained, but patient quality of life decreases due to undesirable side effects
Solution Approach 1:
The patent changes the physical and chemical parameters of drug delivery by formulating bisphosphonates within metal-organic framework structures. This alters the release profile and bioavailability parameters, enabling effective treatment at lower doses that do not compromise patient quality of life.
3Ease of operation
If existing drug delivery systems are used, then drug delivery is provided, but specificity and efficacy in targeting bone metastases are insufficient
Solution Approach 1:
The patent applies local quality by designing metal-organic frameworks with specific functional groups and pore characteristics tailored for bone targeting. The frameworks incorporate bone-seeking moieties that provide localized affinity for bone tissue, enhancing targeting specificity while maintaining drug delivery capability.
Solution Approach 2:
The patent creates composite metal-organic framework structures that combine the advantages of metallic nodes (stability, bioactivity) with organic linkers (tunability, drug loading capacity). This composite structure enables both effective drug delivery and specific targeting of bone metastases through synergistic properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The BBPA-based metal complexes demonstrate controlled drug release, high affinity to bone tissue, and low cytotoxicity, effectively targeting osteolytic metastases with improved bioavailability and reduced side effects, potentially offering a more effective treatment for bone-related diseases.
Implementation Method 1
about 99% of the BBPA could bind to HA in 10 days
Implementation Method 2
porous extended metal complexes capable of encapsulating drugs
Implementation Method 3
hydrothermal synthesis of BBPA with the bioactive metals Ca2+, Zn2+, and Mg2+ leads to four crystals phases
Data Source
AI summary
The invention provides extended bisphosphonate-based metal complexes using benzene1,4-bis(bisphosphonic acid) (BBPA), an analog of benzene 1,4-dicarboxylic acid (BDC). Hydrothermal synthesis of BBPA with the bioactive metals Ca2+, Zn2+, and Mg2+ leads to four crystals phases, namely, BBPA-Ca forms I and II, BBPA-Zn form I, and BBPA-Mg form I. Out of the three structures, BBPA-Ca form II presents large channels (8 Å×12 Å), potentiating the use of this framework to load drugs. Cytotoxicity effects of BBPA was elucidated in a human breast cancer MDA-MB-231 and a normal osteoblast hFOB 1.19 cell lines. The half-maximal inhibitory concentration (IC50) for BBPA used to treat both cell lines were >200 μM at 24, 48, and 72 h of treatment. The BBPA in the range of concentration employed (0-200 μM) was not cytotoxic against these cell lines.